
The Real Pioneers Of Remote Work Could Be Devastated Under The Trump Administration
A mass exodus is predicted if this happens.
A mass exodus is predicted if this happens.
AI is the next big thing, and most developers want to protect those programs and systems. The answer is intellectual property protection and specifically patent protection.
PLI honors Toby J. Rothschild with its inaugural Victor J. Rubino Award for Excellence in Pro Bono Training, recognizing his dedication and impact.
2025 is off to a rip-roaring start in the world of patent law!
These big bonuses keep attracting top talent.
Patent litigation promises to never be a boring enterprise, at least in terms of subject matter.
Pretty big praise.
Meet LexisNexis Protégé™, the new AI assistant that leverages personalization choices controlled by the user or their organization to optimize the individual’s AI experience.
Eli Mazour’s expansion of the Clause 8 podcast experience into the Voice of IP newsletter is a welcome one.
It is likely heartening to Sonos to see the handling of a patent case get overturned by the CAFC in the same week that Sonos lodged its own criticisms of the same judge to the same appellate court.
This year's report highlights how well modern patent litigation has rebounded from the pandemic.
Come on, Roberts!
Learn legal trust accounting best practices to ensure compliance and protect client funds. Discover expert tips to set your firm up for success.
A look at the potential consequences of the Federal Circuit’s reversal of VLSI’s $2 billion March 2021 WDTX verdict against Intel.
Let's revisit some of the conditions that led to the viability of IP Edge’s volume-based nuisance settlement approach to patent litigation.
Move over, hard sciences, because the new design patent bar is making way for lawyers with art backgrounds.
The importance of the networking opportunities at an event like LITFINCON can’t be overstated.
The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA’s official publication of approved products. Such listings delay generic competition, which reduces consumer choice and keeps prices high, the regulator said.